Zhang Junning, Ren Yuehan, Wu Weizhen, Yuan Yi, Wang Jiale, Tang Yi, Zhou Yunqiao, Qiao Yizhuo, Liu Baoqin
Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Front Neurol. 2024 Sep 15;15:1358859. doi: 10.3389/fneur.2024.1358859. eCollection 2024.
Cancer patients frequently suffer pain as one of their symptoms. It includes acute and chronic pain and is one of the most feared symptoms for patients. About one-third of adults actively undergoing cancer treatment suffer from pain related to their condition. Cancer pain control remains suboptimal due to a lack of assessment, knowledge, and access. Fire needle therapy, a traditional Chinese medicine, offers a potentially beneficial addition to current pain management approaches. This protocol outlines a systematic review and meta-analysis to compile evidence and examine the pain-relieving effects and safety of fire needle therapy for cancer patients.
We will systematically search China National Knowledge Infrastructure (CNKI), Wanfang Database, China Biology Medicine disc (CBM), China Science and Technology Journal Database (CSTJ or VIP), PubMed, Web of Science, Embase, Cochrane Central Registry of Controlled Trials (CENTRAL), Chinese Clinical Trial Registry (Chictr), Opengrey, Worldcat, and Scopus from inception through July 2023. Random control trials (RCTs) include all types of cancer patients (age ≥ 18 years) complaining of pain. The primary outcome will be changes in pain intensity measured by Visual Analogue Scale (VAS), Numerical Rating Scale (NRS), Neuropathic Pain Scale (NPS), or Brief Pain Inventory (BPI). Secondary outcomes include quality of life (EORTC QLQ-C30 and GCQ), performance status (KPS), times of burst pain, treatment response rate, the dose reduction of analgesic drugs, and side effects rates. Utilizing the Cochrane risk bias measurement tool: Risk of Bias 2 (RoB 2), the trials' quality will be evaluated, and meta-analysis will be performed using RevMan software (version 5.4).
This systematic review will be the first comprehensive review of the literature to provide a meta-analysis of fire needle therapy for cancer pain, including only Random control trials (RCTs). For the sake of transparency and to avoid future duplication, the publication of this protocol offers a clear illustration of the procedures utilized in this evaluation. The results of our future studies may provide a new approach and theoretical basis for the treatment of cancer pain by medical oncology professionals.
https://www.crd.york.ac.uk/prospero/, identifier CRD42023418609.
癌症患者经常遭受疼痛折磨，这是其症状之一。疼痛包括急性和慢性疼痛，是患者最恐惧的症状之一。约三分之一正在积极接受癌症治疗的成年人患有与病情相关的疼痛。由于缺乏评估、知识和途径，癌症疼痛控制仍未达到最佳状态。火针疗法作为一种中医疗法，可能为当前的疼痛管理方法增添有益补充。本方案概述了一项系统评价和荟萃分析，以收集证据并检验火针疗法对癌症患者的止痛效果和安全性。
我们将系统检索中国知网（CNKI）、万方数据库、中国生物医学文献数据库（CBM）、中国科技期刊数据库（CSTJ或维普）、PubMed、Web of Science、Embase、Cochrane对照试验中心注册库（CENTRAL）、中国临床试验注册中心（Chictr）、Opengrey、Worldcat和Scopus，检索时间从建库至2023年7月。随机对照试验（RCT）纳入所有主诉疼痛的各类癌症患者（年龄≥18岁）。主要结局将是通过视觉模拟量表（VAS）、数字评定量表（NRS）、神经病理性疼痛量表（NPS）或简明疼痛问卷（BPI）测量的疼痛强度变化。次要结局包括生活质量（欧洲癌症研究与治疗组织核心问卷QLQ-C30和特定癌症问卷GCQ）、体能状态（KPS）、爆发性疼痛次数、治疗有效率、镇痛药剂量减少情况及副作用发生率。使用Cochrane偏倚风险评估工具：偏倚风险2（RoB 2）对试验质量进行评估，并使用RevMan软件（5.4版）进行荟萃分析。
本系统评价将是首次对火针疗法治疗癌症疼痛的文献进行全面综述并进行荟萃分析，且仅纳入随机对照试验（RCT）。为确保透明度并避免未来重复研究，本方案的发表清晰展示了本次评估所采用的程序。我们未来研究的结果可能为肿瘤内科专业人员治疗癌症疼痛提供新方法和理论依据。
